Profile data is unavailable for this security.
About the company
Ardelyx, Inc. is a biopharmaceutical company. The Company focuses on discovery, development, and commercialization of advanced medicines that meet significant unmet medical needs. It has two commercial products IBSRELA (tenapanor) and XPHOZAH. Its product pipeline includes RDX013 Program and RDX020 Program. Tenapanor is a small molecule therapy in development for the treatment of or the control of hyperphosphatemia or serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor has a mechanism of action and acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3). IBSRELA is developed for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). XPHOZAH is a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. RDX013 Program is a small molecule potassium secretagogue program for the treatment of hyperkalemia. RDX020 Program is a small molecule for treating metabolic acidosis.
- Revenue in USD (TTM)251.85m
- Net income in USD-72.58m
- Incorporated2007
- Employees267.00
- LocationArdelyx Inc34175 Ardenwood Blvd.FREMONT 94555United StatesUSA
- Phone+1 (510) 745-7047
- Fax+1 (510) 745-0493
- Websitehttps://www.ardelyx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Applied Therapeutics Inc | -211.00k | -187.31m | 1.08bn | 37.00 | -- | 183.07 | -- | -- | -1.53 | -1.53 | -0.0017 | 0.0506 | -0.0028 | -- | -- | -8,440.00 | -246.85 | -140.37 | -- | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Gyre Therapeutics Inc | 191.34m | -76.96m | 1.10bn | 593.00 | -- | 15.95 | -- | 5.74 | -0.2281 | -0.2281 | 1.35 | 0.7366 | 2.83 | -- | 19.64 | 322,656.00 | -95.21 | -73.59 | -154.33 | -99.94 | 96.16 | -- | -33.64 | -205.62 | 3.29 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
| Pharvaris NV | 0.00 | -138.46m | 1.14bn | 82.00 | -- | 3.66 | -- | -- | -2.71 | -2.71 | 0.00 | 5.76 | 0.00 | -- | -- | 0.00 | -54.80 | -36.09 | -58.76 | -38.27 | -- | -- | -- | -- | -- | -41.69 | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -258.08m | 1.17bn | 268.00 | -- | 3.53 | -- | -- | -2.75 | -2.75 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -52.01 | -35.26 | -56.17 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0605 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Arcutis Biotherapeutics Inc | 138.71m | -195.54m | 1.20bn | 296.00 | -- | 7.65 | -- | 8.64 | -1.79 | -1.79 | 1.23 | 1.34 | 0.3799 | 1.04 | 3.49 | 468,608.10 | -53.55 | -65.64 | -75.79 | -71.72 | 89.57 | -- | -140.97 | -1,513.03 | 2.38 | -6.19 | 0.5664 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
| CareDx Inc | 312.78m | -143.56m | 1.21bn | 635.00 | -- | 4.39 | -- | 3.87 | -2.70 | -2.70 | 5.95 | 5.15 | 0.6395 | 5.75 | 5.29 | 492,559.10 | -29.35 | -17.54 | -34.84 | -20.85 | 65.77 | 65.50 | -45.90 | -27.78 | 3.87 | -- | 0.00 | -- | -12.89 | 29.63 | -148.37 | -- | 5.01 | -- |
| Ardelyx Inc | 251.85m | -72.58m | 1.21bn | 267.00 | -- | 7.66 | -- | 4.82 | -0.3113 | -0.3113 | 1.08 | 0.6682 | 0.7664 | 3.76 | 5.22 | 943,254.70 | -22.09 | -46.14 | -26.72 | -57.32 | 85.16 | 88.15 | -28.82 | -240.87 | 3.87 | -5.94 | 0.3888 | -- | 138.61 | 116.66 | 1.70 | -- | 2.04 | -- |
| Enliven Therapeutics Inc | 0.00 | -85.21m | 1.24bn | 57.00 | -- | 4.16 | -- | -- | -1.91 | -1.91 | 0.00 | 6.10 | 0.00 | -- | -- | 0.00 | -29.41 | -42.26 | -30.97 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
| Maravai Lifesciences Holdings Inc | 276.92m | -224.66m | 1.25bn | 580.00 | -- | 3.63 | -- | 4.52 | -1.65 | -1.65 | 2.04 | 1.37 | 0.1562 | 2.98 | 7.43 | 426,030.80 | -18.23 | 12.67 | -23.39 | 15.46 | 46.36 | 74.79 | -116.68 | 37.32 | 9.94 | -1.47 | 0.4746 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Aurinia Pharmaceuticals Inc | 220.36m | -22.55m | 1.26bn | 300.00 | -- | 3.23 | -- | 5.70 | -0.1582 | -0.1582 | 1.53 | 2.71 | 0.3991 | 0.7854 | 5.92 | 734,536.70 | -4.08 | -25.97 | -4.74 | -28.24 | 87.25 | -- | -10.23 | -137.64 | 5.11 | -- | 0.1725 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Novavax Inc | 885.19m | -284.86m | 1.29bn | 1.54k | -- | -- | -- | 1.45 | -2.26 | -2.26 | 6.00 | -3.29 | 0.5254 | 8.19 | 8.10 | 573,683.10 | -16.91 | -46.06 | -79.12 | -269.57 | 63.79 | -- | -32.18 | -75.94 | 0.9272 | -17.46 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| ARS Pharmaceuticals Inc | 2.57m | -49.10m | 1.30bn | 146.00 | -- | 6.47 | -- | 505.09 | -0.5076 | -0.5076 | 0.0266 | 2.07 | 0.011 | -- | -- | 107,000.00 | -21.07 | -20.37 | -22.40 | -21.32 | 76.17 | -- | -1,912.15 | -17,491.75 | 12.52 | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
| Arcus Biosciences Inc | 263.00m | -270.00m | 1.31bn | 577.00 | -- | 2.31 | -- | 4.97 | -3.15 | -3.15 | 3.06 | 6.17 | 0.2153 | -- | 6.83 | 455,805.90 | -22.10 | -15.85 | -26.63 | -18.25 | -- | -- | -102.66 | -103.46 | -- | -- | 0.0768 | -- | 4.46 | 69.54 | -14.98 | -- | 45.01 | -- |
| Syndax Pharmaceuticals Inc | 16.00m | -297.06m | 1.33bn | 112.00 | -- | 3.64 | -- | 83.22 | -3.63 | -3.63 | 0.1949 | 4.28 | 0.0388 | -- | 3.60 | 142,857.10 | -72.01 | -27.90 | -81.78 | -30.15 | -- | -- | -1,856.64 | -324.34 | -- | -- | 0.00003 | -- | -- | -- | -40.19 | -- | -- | -- |
| Day One Biopharmaceuticals Inc | 101.95m | -84.29m | 1.35bn | 174.00 | -- | 2.42 | -- | 13.20 | -1.02 | -1.02 | 1.14 | 5.51 | 0.2009 | -- | -- | 657,761.30 | -16.61 | -- | -17.73 | -- | 97.75 | -- | -82.68 | -- | 14.55 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Ardelyx Inc's reporting currency: US Dollar USD
39.87%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 21.39m | 9.09% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 15.78m | 6.70% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 12.96m | 5.51% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 12.14m | 5.16% |
| Macquarie Investment Management Business Trustas of 30 Sep 2024 | 8.95m | 3.80% |
| Eventide Asset Management LLCas of 30 Sep 2024 | 7.41m | 3.15% |
| Geode Capital Management LLCas of 30 Sep 2024 | 5.49m | 2.33% |
| Millennium Management LLCas of 30 Sep 2024 | 4.01m | 1.70% |
| Rubric Capital Management LPas of 30 Sep 2024 | 3.06m | 1.30% |
| Medical Strategy GmbHas of 31 Jul 2024 | 2.67m | 1.13% |
More ▼
Data from 31 Jul 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
